Papachristodoulou A*, Heidegger I, Virk RK, Di Bernardo M, Kim JY, Laplanca C, Picech F, Schäfer G, De Castro GL, Hibshoosh H, Loda M, Klocker H, Rubin AM, Benson CM, McKiernan JM, Dutta A*, Abate-Shen C. (2024). Metformin overcomes the consequences of NKX3.1 loss to suppress prostate cancer progression. Eur Urol. Apr;85(4):361-372. PMID: 37659962. Authors contributed equally. Impact factor: 25.3. Featured in Columbia University Irving Medical Center’s newsletter.

Papachristodoulou A, Abate-Shen C. (2022). Precision intervention in prostate cancer: re-evaluating who is at risk (Review). Cancer Lett. 538:215709. PMID: 35490919. Impact factor: 9.1. Featured in Elsevier’s Oncology Journal Network’s Prostate Cancer Awareness Month article collection.

Papachristodoulou A*, Rodriguez-Calero A, Panja S, Margolskee E, Virk RK, Milner TA, Pina Martina L, Kim JY, Di Bernardo M, Williams AB, Maliza EA, Caputo JM, Haas C, Wang V, De Castro GL, Wenske S, Hibshoosh H, McKiernan JM, Shen M, Rubin M, Mitrofanova A, Dutta A*, Abate-Shen C. (2021). NKX3.1 localization to mitochondria suppresses prostate cancer initiation. Cancer Discov. 11(9):2316-2333. PMID: 33893149. Authors contributed equally. Impact factor: 30.6.

Commentary by Finch AJ, Baena E. (2021). Spatiofunctional dynamics of NKX3.1 to safeguard the prostate from cancer. Cancer Discov. 11(9):2132-2134. PMID: 34479975.

Lopez-Bujanda ZA, Obradovic A, Nirschl RT, O’Donnell T, Laserson U, Macedo-Gonzales RJ, Crawley L, Papachristodoulou A, Reshef R, Yuan T, Soni KM, Antonarakis ES, Larman BH, Shen M, Muranski P, Drake CG. (2021). TGM4: An immunogenic prostate-restricted antigen. J. Immunother Cancer. 9(6):e001649. PMID: 34193566. Impact factor: 10.3.

Papachristodoulou A*, Silginer M*, Weller M, Schneider H, Hasenbach K, Janicot M, Roth P. (2019). Therapeutic targeting of TGF-β ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas. Clin Cancer Res. 25(23):7189-7201. PMID: 31530630. Authors contributed equally. Impact factor: 10.4.

Papachristodoulou A*, Signorell RD*, Werner B, Brambila D, Luciani P, Cavusoglu M, Grandjean J, Silginer M, Rudin M, Martin E, Weller M, Roth P, Leroux JC. (2019). Chemotherapy sensitization of glioblastoma by ultrasound-mediated delivery of therapeutic liposomes. J. Control Release. 295:130-139. PMID: 30537486. Authors contributed equally. Impact factor: 10.5.

Signorell RD*, Papachristodoulou A*, Xiao J, Arpagaus B, Casalini T, Grandjean J, Thamm J, Steiniger F, Luciani P, Brambilla D, Werner B, Martin E, Weller M, Roth P, Leroux JC. (2018). Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. Int J Pharm. 536(1): 388-396. PMID: 29198811. Authors contributed equally. Impact factor: 5.3.

Seystahl K, Papachristodoulou A, Burghardt I, Schneider H, Hasenbach K, Janicot M, Roth P, Weller M. (2017). Biological role and therapeutic targeting of TGF-beta3 in glioblastoma. Mol. Cancer Ther. 16(6): 1177-1186. PMID: 28377490. Impact factor: 5.4.